- Policy
- Pitavastatin-Ezetimibe by JW Pharmaceutical was applied
- by Lee, Tak-Sun Mar 22, 2021 06:18am
- JW Pharmaceutical is participating in the Statin-Ezetimibe hyperlipidemia complex market, which has more than 600 products in Korea. It is a combination of Livalo (Pitavastatin) and Ezetimibe. According to industry sources on the 21st, JW Pharmaceutical recently applied for permission for Pitavastatin-Ezetimibe to the MFDS. It was known as
- Company
- Big 5 to prescribe a novel antifungal drug Cresemba
- by Eo, Yun-Ho Mar 22, 2021 06:17am
- The Big Five South Korean general hospitals have registered a novel antifungal drug Cresemba for prescription. Pharmaceutical industry sources reported the Drug Committee (DC) at all of the Big Five general hospitals in South Korea, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital and Severa
- Policy
- New standard for Adcetris combination has been established
- by Lee, Hye-Kyung Mar 22, 2021 06:17am
- Takeda's antibody-drug conjugate (ADC) and Adcetris (Brentuximab) are now available in combination with chemotherapy during the first-line administration of patients with non-Hodgkin lymphoma and Hodgkin lymphoma. The HIRA announced on the 17th that the revised bill 'Details on the criteria and methods for applying medical care benefits t
- Product
- This situation of mixing Lyrica with other doses is absurd
- by Kang, Shin-Kook Mar 22, 2021 06:16am
- When it was confirmed that Pfizer Korea's Lyrica had mixed drugs with different doses, The Korean Pharmaceutical Association urged a countermeasure to prevent recurrence. The KPA(Chairman Dae-eop Kim) made a statement on the 17th, saying, "The case where different doses of pharmaceuticals are mixed & packaging in the bottle is a serious prob
- Company
- Keytruda is expected to expand its indications
- by Eo, Yun-Ho Mar 19, 2021 06:29am
- Keytruda, an immune anticancer drug, is expected to expand its indications for the first-line therapy for colon cancer and esophageal cancer. According to industry sources, MSD Korea recently submitted an application for additional indications about PD-1 inhibitor Keytruda's (Pembrolizumab) ▲MSI-H, microsatellite instability high or dMMR, fi
- Opinion
- [Reporter’s Eye] For unbiased KPBMA ethics committee
- by Mar 19, 2021 06:28am
- Industry-representing associations are often perplexed among various opinions of businesses of all sizes. Unlike small and medium-sized companies urging the regulation to be versatile for the survival of many companies, large corporations focus more on industry support and advancement. Often, the companies express contrasting opinions on a s
- Policy
- AZ vaccine plan can be updated after reviewing EMA's results
- by Lee, Jeong-Hwan Mar 19, 2021 06:28am
- KCDA Commissioner Jeong Eun Kyeong said that after reviewing the results of the analysis of side effects such as blood clots of the AstraZeneca COVID-19 vaccine of the EMA, follow-up measures such as discontinuation of vaccination in Korea will be decided. On the 17th, Commissioner Jeong responded to inquiries from the People Power Party
- Policy
- AZ and Pfizer COVID-19 vaccines to arrive on Mar. 24
- by Kim, Jung-Ju Mar 19, 2021 06:27am
- The detailed arrival schedule for the COVID-19 vaccines to be supplied this month has been finalized. When the vaccines arrive to South Korea, they would be distributed to 22 inoculation centers around the country, where the vaccines would be used to inoculate elderly citizens aged over 75, and elderly care center occupants and workers f
- Policy
- Pfizer vaccine is recommended for seniors 65 and older
- by Lee, Jeong-Hwan Mar 19, 2021 06:27am
- It is suggested that the elderly 65 years of age or older with underlying diseases should be vaccinated with Pfizer vaccine, not AstraZeneca vaccine. Due to the risk of blood clots, some foreign countries, including Europe, have stopped vaccinating AstraZeneca vaccine. The question is whether Korea should also recommend Pfizer vaccination to
- Policy
- Sovaldi's criteria for re-examination are relaxed
- by Lee, Tak-Sun Mar 18, 2021 08:26am
- Re-examination criteria of Sovaldi (Sofosbuvir) and Harvoni (Sofosbuvir-Ledipasvir) by Gilead Science Korea are relaxed. This is because the emergence of new drugs and the continuation of COVID-19 epidemic make it difficult to conduct sufficient usability surveys. Since the recently released hepatitis C treatment can be cured, the number of
